See more : Koramco Energy Plus Reit (357120.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Bio Plus Co., Ltd (099430.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio Plus Co., Ltd, a leading company in the industry within the sector.
- NeuroBo Pharmaceuticals, Inc. (NRBO) Income Statement Analysis – Financial Results
- Nofoth Food Products Company (9556.SR) Income Statement Analysis – Financial Results
- Centrais Elétricas de Santa Catarina S.A. (CLSC3.SA) Income Statement Analysis – Financial Results
- Twist Bioscience Corporation (TWST) Income Statement Analysis – Financial Results
- Peer to Peer Network (PTOP) Income Statement Analysis – Financial Results
Bio Plus Co., Ltd (099430.KQ)
Website: https://www.ubioplus.co.kr
About Bio Plus Co., Ltd
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 65.04B | 56.72B | 37.42B | 24.37B | 17.02B |
| Cost of Revenue | 25.47B | 22.91B | 13.77B | 7.80B | 5.83B |
| Gross Profit | 39.57B | 33.81B | 23.65B | 16.56B | 11.19B |
| Gross Profit Ratio | 60.84% | 59.60% | 63.19% | 67.98% | 65.73% |
| Research & Development | 1.17B | 1.08B | 435.18M | 276.05M | 214.69M |
| General & Administrative | 1.05B | 660.66M | 486.12M | 207.75M | 80.94M |
| Selling & Marketing | 2.18B | 2.05B | 1.39B | 739.94M | 950.64M |
| SG&A | 3.23B | 2.72B | 1.87B | 947.69M | 3.62B |
| Other Expenses | 7.15B | -59.00M | -3.72M | -3.46M | 0.00 |
| Operating Expenses | 11.55B | 8.53B | 5.42B | 4.24B | 4.41B |
| Cost & Expenses | 37.02B | 31.45B | 19.19B | 12.04B | 10.24B |
| Interest Income | 2.44B | 1.07B | 158.26M | 18.18M | 25.66M |
| Interest Expense | 60.28M | 13.30M | 521.47M | 58.16M | 84.67M |
| Depreciation & Amortization | 2.49B | 1.89B | 1.30B | 1.01B | 866.82M |
| EBITDA | 30.52B | 27.49B | 19.52B | 13.34B | 7.76B |
| EBITDA Ratio | 46.92% | 49.94% | 52.53% | 54.04% | 45.56% |
| Operating Income | 28.03B | 25.27B | 18.23B | 12.33B | 6.89B |
| Operating Income Ratio | 43.09% | 44.56% | 48.71% | 50.59% | 40.47% |
| Total Other Income/Expenses | 4.71B | 1.04B | -4.06B | -193.11M | -169.07M |
| Income Before Tax | 32.74B | 27.47B | 14.17B | 12.13B | 6.72B |
| Income Before Tax Ratio | 50.34% | 48.43% | 37.86% | 49.80% | 39.48% |
| Income Tax Expense | 5.32B | 6.76B | 3.49B | 2.43B | 1.10B |
| Net Income | 25.58B | 21.14B | 10.72B | 9.70B | 5.62B |
| Net Income Ratio | 39.33% | 37.27% | 28.66% | 39.82% | 33.04% |
| EPS | 445.00 | 372.00 | 206.00 | 194.50 | 233.00 |
| EPS Diluted | 433.00 | 371.00 | 203.50 | 188.75 | 227.50 |
| Weighted Avg Shares Out | 57.48M | 58.07M | 51.81M | 49.89M | 24.13M |
| Weighted Avg Shares Out (Dil) | 59.08M | 58.12M | 52.56M | 51.41M | 24.72M |
Source: https://incomestatements.info
Category: Stock Reports